-$0.17 Earnings Per Share Expected for Amyris Inc (AMRS) This Quarter

Equities research analysts predict that Amyris Inc (NASDAQ:AMRS) will announce earnings of ($0.17) per share for the current fiscal quarter, Zacks reports. Two analysts have made estimates for Amyris’ earnings. The lowest EPS estimate is ($0.23) and the highest is ($0.11). Amyris posted earnings of ($1.14) per share during the same quarter last year, which indicates a positive year over year growth rate of 85.1%. The business is scheduled to announce its next quarterly earnings results on Tuesday, November 13th.

According to Zacks, analysts expect that Amyris will report full-year earnings of ($1.41) per share for the current fiscal year, with EPS estimates ranging from ($1.56) to ($1.26). For the next year, analysts forecast that the company will report earnings of $0.19 per share, with EPS estimates ranging from $0.16 to $0.22. Zacks’ EPS averages are a mean average based on a survey of analysts that that provide coverage for Amyris.

Amyris (NASDAQ:AMRS) last posted its quarterly earnings data on Monday, August 6th. The biotechnology company reported ($0.38) EPS for the quarter, missing analysts’ consensus estimates of ($0.30) by ($0.08). The company had revenue of $24.81 million during the quarter, compared to analyst estimates of $37.52 million. The firm’s revenue was down 3.4% on a year-over-year basis. During the same quarter in the prior year, the firm posted ($1.32) earnings per share.

A number of analysts recently commented on the company. BidaskClub raised Amyris from a “hold” rating to a “buy” rating in a research note on Wednesday, August 15th. ValuEngine lowered Amyris from a “buy” rating to a “hold” rating in a research note on Friday, June 1st. B. Riley set a $10.00 price objective on Amyris and gave the company a “buy” rating in a research note on Tuesday, May 29th. HC Wainwright reaffirmed a “buy” rating and set a $15.00 price objective on shares of Amyris in a research note on Tuesday, August 7th. Finally, Zacks Investment Research raised Amyris from a “strong sell” rating to a “hold” rating in a research note on Tuesday, July 17th. One analyst has rated the stock with a sell rating, one has given a hold rating, three have given a buy rating and one has issued a strong buy rating to the stock. The stock presently has an average rating of “Buy” and a consensus price target of $9.13.

Shares of AMRS traded up $0.31 during trading hours on Thursday, reaching $8.32. 71,276 shares of the company traded hands, compared to its average volume of 1,103,656. The company has a quick ratio of 0.38, a current ratio of 0.42 and a debt-to-equity ratio of -0.24. The firm has a market cap of $400.43 million, a P/E ratio of -2.72 and a beta of 0.18. Amyris has a fifty-two week low of $2.82 and a fifty-two week high of $9.22.

In other Amyris news, COO Eduardo Alvarez bought 11,877 shares of Amyris stock in a transaction that occurred on Wednesday, September 5th. The shares were purchased at an average cost of $8.45 per share, for a total transaction of $100,360.65. Following the completion of the transaction, the chief operating officer now owns 331,877 shares of the company’s stock, valued at approximately $2,804,360.65. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CFO Kathleen Valiasek bought 14,000 shares of Amyris stock in a transaction that occurred on Wednesday, August 22nd. The shares were acquired at an average price of $7.20 per share, for a total transaction of $100,800.00. Following the completion of the transaction, the chief financial officer now directly owns 228,630 shares of the company’s stock, valued at approximately $1,646,136. The disclosure for this purchase can be found here. Over the last quarter, insiders have purchased 50,877 shares of company stock worth $393,161 and have sold 8,824,625 shares worth $54,897,886. Corporate insiders own 21.80% of the company’s stock.

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Dynamic Technology Lab Private Ltd purchased a new position in Amyris during the first quarter worth about $110,000. Rhumbline Advisers purchased a new position in Amyris during the second quarter worth about $147,000. Renaissance Technologies LLC purchased a new position in Amyris during the second quarter worth about $167,000. Element Capital Management LLC purchased a new position in Amyris during the first quarter worth about $227,000. Finally, Schwab Charles Investment Management Inc. purchased a new position in shares of Amyris in the 2nd quarter worth about $292,000. Hedge funds and other institutional investors own 27.90% of the company’s stock.

Amyris Company Profile

Amyris, Inc provides various alternatives to a range of petroleum-sourced products worldwide. The company uses its industrial bioscience technology to design microbes primarily yeast, as well as to convert plant-sourced sugars into renewable ingredients. It produces and sells Biofene that converts to squalane, which is used as an emollient in cosmetics and other personal care products; and natural oils and aroma chemicals for the flavors and fragrances market.

Featured Article: How is a Moving Average Calculated?

Get a free copy of the Zacks research report on Amyris (AMRS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Amyris (NASDAQ:AMRS)

Receive News & Ratings for Amyris Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amyris and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply